Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial
Alimentary Pharmacology & Therapeutics · 2023-06 · 57 (11) · 1258-1271
DOI: 10.1111/apt.17426 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 03.03.2023. Verfasst von David Gunn und 21 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Efficacy and Mechanism Evaluation Programme.
Abstract (Originalsprache)
Background
Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS‐D).
Aim
To conduct a 12‐week parallel group, randomised, double‐blind, placebo‐controlled trial of ondansetron 4 mg o.d. (titrated up to 8 mg t.d.s.) in 400 IBS‐D patients. Primary endpoint: % responders using the Food and Drug Administration (FDA) composite endpoint. Secondary and mechanistic endpoints included stool consistency (Bristol Stool Form Scale) and whole gut transit time (WGTT). After literature review, results were pooled with other placebo‐controlled trials in a meta‐analysis to estimate relative risks (RR), 95% confidence intervals (CIs) and number needed to treat (NNT).
Results
Eighty patients were randomised. On intention‐to‐treat analysis, 15/37 (40.5%; 95% CI 24.7%–56.4%) met the primary endpoint on ondansetron versus 12/43 (27.9%; 95% CI 14.5%–41.3%) on placebo ( p = 0.19). Ondansetron improved stool consistency compared with placebo (adjusted mean difference − 0.7; 95% CI −1.0 to−0.3, p < 0.001). Ondansetron increased WGTT between baseline and week 12 (mean (SD) difference 3.8 (9.1) hours, versus placebo −2.2 (10.3) hours, p = 0.01). Meta‐analysis of 327 patients from this, and two similar trials, demonstrated ondansetron was superior to placebo for the FDA composite endpoint (RR of symptoms not responding = 0.86; 95% CI 0.75–0.98, NNT = 9) and stool response (RR = 0.65; 95% CI 0.52–0.82, NNT = 5), but not abdominal pain response (RR = 0.95; 95% CI 0.74–1.20).
Conclusions
Although small numbers meant the primary endpoint was not met in this trial, when pooled with other similar trials meta‐analysis suggests ondansetron improves stool consistency and reduces days with loose stool and urgency. Trial registration – http://www.isrctn.com/ISRCTN17508514
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK.
- Nottingham Digestive Diseases Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
- Barts and The London School of Medicine and Dentistry, London, UK.
- Wingate Institute of Neurogastroenterology, Queen Mary University of London, London, UK.
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
- Royal Stoke Hospital, University Hospitals of North Midlands NHS Trust, Stoke, UK.
ORCID-Profile: David Gunn, Maura Corsetti, John Mclaughlin, Lesley Houghton, Alexander C Ford, Robin Spiller
Förderung
- Efficacy and Mechanism Evaluation Programme
Zitieren
APA
Gunn, D., Topan, R., Barnard, L., Fried, R., Holloway, I., Brindle, R., Corsetti, M., Scott, M., Farmer, A., Kapur, K., Sanders, D., Eugenicos, M., Trudgill, N., Whorwell, P., Mclaughlin, J., Akbar, A., Houghton, L., Dinning, P. G., Aziz, Q., …, & Spiller, R. (2023). Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology & Therapeutics, 57(11), 1258-1271. https://doi.org/10.1111/apt.17426
Vancouver
Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, et al. Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology & Therapeutics. 2023;57(11):1258-1271. doi:10.1111/apt.17426
BibTeX
@article{Gunn2023,
author = {Gunn, David and Topan, Rabia and Barnard, Lorna and Fried, Ron and Holloway, Ivana and Brindle, Richard and Corsetti, Maura and Scott, Mark and Farmer, Adam and Kapur, Kapil and Sanders, David and Eugenicos, Maria and Trudgill, Nigel and Whorwell, Peter and Mclaughlin, John and Akbar, Ayesha and Houghton, Lesley and Dinning, Phil G and Aziz, Qasim and Ford, Alexander C and Farrin, Amanda J and Spiller, Robin},
title = {Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {57},
number = {11},
pages = {1258--1271},
doi = {10.1111/apt.17426}
}
EUVIMED